



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 21 Issue 3 Version 1.0 Year 2021
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Prevalence of Carbapenem Resistant *Klebsiella Pneumoniae* in North India

By Puneeta Singh, Shalabh Malik & Vandana Lal

Abstract- Objectives: The aim of this retrospective observational study was to investigate the burden and current antimicrobial susceptibility of Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) isolated from diverse samples.

Methods: 3256 *Klebsiella pneumoniae* isolates enrolled in this retrospective study, covering a 9-month period from January 2021 to September 2021. It focused on analyses the prevalence and characterization of Carbapenem-resistant *K. pneumoniae* strain isolated from the diverse samples of Blood, Urine, Pus, Body fluids, and Sputum analyzed at the microbiology laboratory of the Dr. Lal Path Labs, Delhi, North India.

Keywords: carbapenem-resistant *klebsiella pneumoniae* (CRKP), carbapenem-sensitive *klebsiella pneumoniae* (CSKP), extremely drug resistant (XDR), pan drug-resistant (PDR), amikacin, tigecycline, fosfomycin.

GJMR-C Classification: NLMC Code: QW 4, WC 202



Strictly as per the compliance and regulations of:



© 2021. Puneeta Singh, Shalabh Malik & Vandana Lal. This research/review article is distributed under the terms of the Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). You must give appropriate credit to authors and reference this article if parts of the article are reproduced in any manner. Applicable licensing terms are at <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

Prevalence of Carbapenem Resistant *Klebsiella Pneumoniae* in North India

Puneeta Singh ^α, Shalabh Malik ^σ & Vandana Lal ^ρ

Abstract- Objectives: The aim of this retrospective observational study was to investigate the burden and current antimicrobial susceptibility of Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) isolated from diverse samples.

Methods: 3256 *Klebsiella pneumoniae* isolates enrolled in this retrospective study, covering a 9-month period from January 2021 to September 2021. It focused on analyses the prevalence and characterization of Carbapenem-resistant *K. pneumoniae* strain isolated from the diverse samples of Blood, Urine, Pus, Body fluids, and Sputum analyzed at the microbiology laboratory of the *Dr. Lal Path Labs*, Delhi, North India.

Results and Discussion: Of the total 3662 isolates of *Klebsiella pneumoniae*, 1637 (44.7%) strains were carbapenem resistant. The majority of CRKP isolates were from Blood (67.1%) followed by Pus (61.2%), Body fluids (59.4%), Urine (42.5%), Respiratory (41.8%) and genital vaginal (13.8%). In this study, it appeared that only Tigecycline could be a good choice (susceptibility of 57%), at the same time Trimethoprim/Sulfamethoxazole (TM/SXT) and amikacin might be an alternative, its susceptibility was only slightly higher than 40% and 50%, respectively. In addition, our huge sample study possible to draw definitive conclusions for Fosfomycin (susceptibility of 71%) recommended as a supplement in treating CRKP in UTIs if the organism tests as susceptible.

These data highlight the need for regular surveillance of microbial resistance in India and guide the use of antimicrobial agents to improve infection control, prevent the misuse of carbapenems that has contributed to the appearance of extremely drug-resistant (XDR), and Pan drug-resistant (PDR) isolates.

Conclusions: Our findings concluded that the CRKP existed in north India among diverse samples that can also be associated with the presence in a high-risk because we are sitting on a time bomb of XDR and PDR bacterial infections if we do not take the necessary steps in time, then we have limited or no options for treatment. Therefore, the continuous monitoring of carbapenems is necessary to prevent the national and transnational spread of these isolates, especially in the cases when the healthcare facilities are inadequate.

Keywords: carbapenem-resistant *klebsiella pneumoniae* (CRKP), carbapenem-sensitive *klebsiella pneumoniae* (CSKP), extremely drug resistant (XDR), pan drug-resistant (PDR), amikacin, tigecycline, fosfomycin.

Corresponding Author α: Department of Microbiology and Serology, Dr Lal Path Labs National Reference Laboratory, Delhi, India.
e-mail: Puneeta.singh@lalpathlabs.com

Author σ: Department of Microbiology and Serology, Dr Lal Path Labs National Reference Laboratory, Delhi, India.

Author ρ: Dr Lal Path Labs National Reference Laboratory, Delhi, India.

I. INTRODUCTION

K. pneumoniae, described by Edwin Klebs in 1875, is a gram-negative bacterium belonging to the *Enterobacteriaceae* family. It caused severe infections in critically ill patients, newborns, immunocompromised individuals or those with other risk factors in healthcare establishments [1, 3]. Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) has emerged as a major nosocomial pathogen worldwide and constitutes a significant growing public health threat in developing and developed countries due to the indiscriminate consumption of carbapenem antibiotics that has accelerated the incidence of antibiotic resistance in recent years [1, 5, 10]. Carbapenem resistance is typically mediated by the production of carbapenem-hydrolyzing enzyme through the evolution of high-risk clones by acquiring, retaining, and efficiently transmitting resistance genes, and unrestricted consumption promoted the rising trend as well. Carbapenem-resistant *Enterobacteriaceae* were first described in the early 1990s, and the isolation of carbapenem resistant *K. pneumoniae* strains occurred sporadically throughout that decade [11]. Over the past few years, however, the recovery of carbapenem-resistant *Klebsiella pneumoniae* strains from diverse clinical specimens has increased at an alarming rate because carbapenems are widely used to treat infections, especially those caused by *Enterobacteriaceae*, a producer of extended-spectrum β -lactamase (ESBL).

CRKP bloodstream infections are associated with higher mortality than other infection types of CRKP and require treatments timely, especially in hematological patients. This study was used to establish a risk prediction model of CRKP in this region and seek appropriate treatment in this population. Bloodstream infections caused by CRKP increase the rate of treatment failure and death. Recent estimates suggest that attributable mortality may be as high as 44%, particularly in the setting of bacteremia, with total economic costs exceeding \$553 million annually in the United States based on current incidence [1]. Previous studies have found a crude mortality rate ranging from 44% to 33% for diverse infections caused by carbapenem-resistant *K. pneumoniae* [5, 12]. In our region, where *K. pneumoniae* represented 18% of all urinary *Enterobacteriales* isolates and the second leading

cause of health care-associated UTIs, and CRKP is increasingly implicated that accounts for 42.5% of all urinary *K. pneumoniae* isolates. In line with our study, Patients in the ICU are at a risk of infections caused by carbapenem-resistant *K. pneumoniae*, which is emerging as a risk to causes various nosocomial infections, notably 40% in respiratory tract infections, 59-60% of body fluids and pus samples. Therefore, we set out this study to determine the prevalence of carbapenem resistance among clinical *K. pneumoniae* isolates originated from different sections of the hospitals, which affiliated with our lab and walk-in lab in Delhi, northern region of India.

II. MATERIAL AND METHODS

This retrospective study was performed in the Microbiology department of *Dr. Lal Path Labs* in Delhi, North India. A total of 3662 *K. pneumoniae* isolates recovered from diverse samples were correctly identified using a matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS, Bruker Daltonics, Bremen, Germany).

Antibiotic susceptibility testing done by VITEK-2 (Biomerieux) system from the pure culture of isolated colonies of the *Klebsiella pneumonia* on Bloodagar; the Gram-negative bacteria were inoculated on to N405 card, and the breakpoint (susceptible, intermediate, or resistant) was interpreted according to Enterobacterales M100-S31 provided by the Clinical and Laboratory Standards Institute (CLSI) standards. The antibiotic susceptibility tests were conducted for Ampicillin, Amoxicillin clavulanic acid, Piperacillin-tazobactam, Ciprofloxacin, Levofloxacin, Cefuroxime, Ceftriaxone, Cefepime, Cefoperazone/sulbactam, Amikacin, Gentamicin, Trimethoprim-sulfamethoxazole, Ertapenem, Meropenem, Imipenem, Fosfomycin, and Nitrofurantoin. All ASTs, except Tigecycline, were interpreted according to the criteria of Enterobacterales in the Clinical and Laboratory Standard Institute (CLSI) guideline (2021) [15]. The interpretation of Tigecycline followed the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2021). However, Colistin was recommended to treat CRKP infection by

EUCAST. Thus, Colistin susceptibility was not routinely tested or included in our study because of its severe side effects such as nephrotoxicity, neuromuscular blockade.

In this study, Minimum inhibitory concentration (MIC) breakpoints were used as a testing method that have to detected carbapenem-resistance, and this test can be carried out using broth micro dilutions by automated antimicrobial susceptibility testing (AST) systems (VITEK-2). CRKP was defined as isolated *Klebsiella pneumoniae* strains resistant to carbapenem agents, including ertapenem, meropenem, or imipenem. *Klebsiella pneumoniae* isolates are associated with a suspicion of carbapenemase production based on updated carbapenem breakpoints (imipenem or meropenem or ertapenem MICs according to breakpoints defined by the CLSI at least $\geq 2\mu\text{g/mL}$). ATCC700603 was used as the quality control strain for the antibiotic susceptibility tests. To avoid duplicate counts, only the first strain was included for every patient, based on the ID number.

Statistical Analysis: The analysis was done using the Statistical Module of Myla Application from bioMerieux. Age, gender, antibiotic sensitivity and resistance with MIC were included as variables in this study. Myla is a browser-based application that consolidates and covers the microbiology data into actionable information. The Statistical Reporting Module is a specific MYLA(r) computer application which allows to Manage, Configure and generate different types of Microbiology Statistical Report in few clicks."

III. RESULTS

Of the total 3662 isolates of *Klebsiella pneumonia* from the diverse clinical specimens, 1637 isolates (44.7%) were confirmed to be 100% carbapenem-resistant, in which the highest occurrence of CRKP was found in blood samples comprising (67.1%) followed by Pus (61.2%), Body fluids (59.4%), Urine (42.7%), Respiratory (41.9%) and genital vaginal (13.8%) respectively (Table 1).

Table 1: Distribution of Carbapenem-Resistant *K. pneumoniae* in diverse samples during January to September 2021.

Samples	Total <i>K. pneumoniae</i> isolates N=3662	Carbapenem resistant <i>K. pneumoniae</i> (CRKP) isolates N=1637 (44.7%)
Blood	91	61 (67.1%)
Pus	165	101 (61.2%)
Body fluids	185	110 (59.4%)
Respiratory	191	80 (41.9%)
Genital vaginal	29	4 (13.8%)
Urine	3001	1281(42.7%)

Among the total 1637 CRKP isolates, 923 (56.4%) were isolated from males, while the remaining 714 (43.6%) were from females. Among these CRKP strains, 75% of patients were generally elderly (with a

range of 51 to >65 years), followed by younger adults (10.1%), adults (9.3%) and children (5.7%), respectively (Figure 1).

Age wise prevalence of Carbapenem resistant *K. pneumoniae* in different age groups.




Figure 1: Age-specific distribution of Carbapenem-Resistant *Klebsiella pneumoniae* during January to September 2021.

Table 2: Percentage of Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) in diverse samples based on cumulative interpretation in different age groups during January to September 2021.

Age Specimens	0-12	13-35	36-50	51-65	>=66
Blood (n=61)	18 (29.5)	15 (24.6)	8 (13.1)	10 (16.4)	10 (16.4)
Pus (n=101)	3 (2.9)	31 (30.7)	23 (22.8)	20 (19.8)	24 (23.8)
Body Fluids (110)	2 (1.8)	22 (20)	15 (13.6)	35 (31.8)	36 (32.7)
Respiratory (80)	0	6 (7.5)	9 (11.3)	30 (37.5)	35 (43.8)
Urine (1281)	70 (5.4)	87 (6.8)	98 (7.7)	278 (21.7)	748 (57.7)
Genital (4)	0	3 (75)	0	1 (25)	0

Distribution of Carbapenem resistant *K. pneumoniae* in different age groups isolated from diverse samples during January to September 2021.




Figure 2

This study represents the prevalence of carbapenem-resistant *K. pneumoniae* in the different clinical samples in different age group has shown the maximum occurrence of CRKP in blood in children. Along with this, our study shows that the young age group (13-35) has the highest percentage of CRKP in

pus. In addition, present data reported extreme prevalence of CRKP in Body fluids, Respiratory samples is most associated in elderly people ranging from 51 to >=66 age group while more than 50% infection with CRKP in Urine specimens associated with elderly >=66 age group (Table 2, Figure-2).

Table 3: Antibiotic Susceptibility pattern with cumulative MIC interpretation of Carbapenem against Carbapenem Sensitive *Klebsiella pneumoniae* (CSKP) isolated from diverse samples.

Total No.	Range	CSKP N=2025 (55.3%)		CSKP MIC ($\mu\text{g/ml}$) 50/90
		Sensitive%	R%	
Ertapenem	$\leq 0.5 - \geq 2$	97.9%	2.1%	0.5/0.5
Meropenem	$\leq 1 - \geq 4$	97.2%	2.8%	$\leq 0.25/0.25$
Imepenem	$\leq 1 - \geq 4$	97.6%	2.4%	$\leq 0.25/0.5$

Table 4: Antibiotic Susceptibility pattern with cumulative MIC interpretation of Carbapenem against Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) isolated from diverse samples.

Total No.	Range	CRKPN=1637 (44.7%)		CRKP MIC ($\mu\text{g/ml}$) 50/90
		Sensitive%	R%	
Ertapenem	$\leq 0.5 - \geq 2$	0%	100	8/8
Meropenem	$\leq 1 - \geq 4$	0%	100	4/16
Imepenem	$\leq 1 - \geq 4$	0%	100	4/16

In this study, *K. Pneumoniae* isolates originated from different sections of the hospitals, which are affiliated with our lab and walk in the lab. This study uses current breakpoints recommended by CLSI (M100-S31) for carbapenem interpretation, 1637 (44.7%) out of 3662 *K. pneumoniae* isolates were nonsusceptible (intermediate and resistant) to Ertapenem, Meropenem and Imipenem recognized as Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP). Susceptibility pattern and their MIC value of CRKP isolates was as follows:

Ertapenem (0%; MIC_{50/90} 8ug/ml), Meropenem and Imipenem (0%; MIC_{50/90} 4-to16ug/ml) respectively. Whereas 2025 (55.3%) recognized as Carbapenem Sensitive *Klebsiella pneumoniae* (CSKP) were susceptible to carbapenem 97% and MIC values of the tested β -lactam antibiotics were as follows: MIC_{50/90} 0.5ug/ml for Ertapenem, MIC_{50/90} ≤ 0.25 to 0.5ug/ml for Meropenem, and Imipenem respectively in all tested strains [Table 3, 4].

Table 5: Percentage of cumulative MIC interpretation and Sensitivity of other antibiotics against Carbapenem Sensitive *Klebsiella pneumoniae* (CSKP) and Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) from all age groups during Jan to September 2021.

ORGANISM ANTIBIOTICS	Range	CSKP N=2025 (S%)	CSKPMIC ($\mu\text{g/ml}$) 50/90	CRKP N=1637 (S%)	CRKPMIC ($\mu\text{g/ml}$) 50/90
Ampicillin	$\leq 8 - \geq 32$	0.9	32/32	0	32/32
Amoxicillin/clavulanic acid	$\leq 8 - \geq 32$	75%	$\leq 2/32$	23%	32/32
Piperacillin/tazobactam	$\leq 16 - \geq 128$	92%	$\leq 4/16$	34%	128/128
Cefuroxime	$\leq 4 - \geq 32$	76%	2/64	4%	64/64
Cefuroxime/Axetil	$\leq 4 - \geq 32$	73%	2/64	3%	64/64
Ceftriaxone	$\leq 1 - \geq 4$	95%	1/1	6%	64/64
Cefoperazone/sulbatam	$\leq 16 - \geq 64$	97%	$\leq 8/\leq 8$	43%	64/64
Cefepime	$\leq 2 - \geq 16$	96%	1/1	35%	32/64
Amikacin	$\leq 16 - \geq 64$	97%	$\leq 2/2$	54%	4/64
Gentamicin	$\leq 4 - \geq 16$	96%	$\leq 1/\leq 1$	47%	8/16
Ciprofloxacin	$\leq 0.25 - \geq 1$	62%	0.5/2	12%	4/4
Tigecycline	$\leq 0.5 - \geq 2$	86%	$\leq 0.5/2$	57%	0.5/8
Trimethoprim/sulfamethoxazole	$\leq 20 - \geq 80$	91%	$\leq 20/40$	42%	40/320
Fosfomycin	$\leq 64 - \geq 256$	94%	$\leq 16/64$	71%	$\leq 16/256$
Nitrofurantoin	$\leq 32 - \geq 128$	46%	64/128	16%	256/512

In our study, it appeared that Tigecycline was still the good choice of CRKP, with susceptibility (57%) Other options might be amikacin (54%) and TM/SXT (42%) and their MIC values were as follows: Tigecycline (57%; MIC_{50/90} 0.5/8 ug/ml), Amikacin (54%; MIC_{50/90} 4/64 ug/ml), TM/SXT (42%; MIC_{50/90} 40/320ug/ml) and Fosfomycin (71%; MIC_{50/90} 16/256ug/ml). However, the susceptibility to these antibiotics was only slightly higher than 50%. While other antibiotics sensitive pattern, which

were tested against CRKP isolates, was as follows: Amoxicillin/clavulanic acid (23%), Ceftriaxone (6%), Cefuroxime (4%), and Ciprofloxacin (12%). In recent years, Fosfomycin (susceptibility of 71%) has been recommending as a supplement in treating CRKP infection, although the CLSI standards propose it only for the treatment of urinary tract infections. The antibiogram and MIC results of the CSKP and CRKP isolates for all tested drugs are given in Table 5. Among

1637 CRKP isolates, 36(2.2%) isolates were resistant to all tested antibiotics (pan drug-resistant); these isolates did not respond to the last-resort antimicrobial Tigecycline.

IV. DISCUSSION

Klebsiella pneumoniae is among one of the most commonly detected multidrug-resistant member of the Enterobacteriales family emergence of carbapenem resistant *Klebsiella pneumoniae* (CRKP) has resulted in limited effective treatment strategies, posing a healthcare threat worldwide [1-10]. The global prevalence of carbapenem-resistant *Klebsiella pneumoniae* has become alarming especially in developing and developed countries with inconsistent antibiotic policies. To our knowledge, this was the first study to focus on the burden and susceptibility of carbapenem-resistant *K. pneumoniae* (CRKP) in diverse samples present alarming in north India that emphasizes contributing factor to extensive drug resistance, and their recent acquisition and dissemination likely predicted pan-drug resistance shortly. However, blood, urine, sputum, tracheal secretion and pus were the major source of CRKP worldwide, which is similar to our findings [2, 4-6, 8-10].

Our results present a worrying trend of CRKP 44.7% among *K. Pneumoniae* isolates, which is similar to the previous study where Egyptian literature showed a prevalence of 44.3% of CRKP isolates [2, 5]. Similarly, other studies showed varying prevalence rates from 20 to 60% in India and other countries [3,5 7-9]. In our study, the CRKP was found to be highest in elderly patients ranging 51 to ≥ 66 which is similar to the other studies [2, 4-6]

Our study reported that carbapenem-resistant *K. pneumoniae* was the strongest predictor of bloodstream infection among all the clinical samples studied Blood contained the highest percentage of CRKP, and this finding was also consistent with a study done in south India [10], but we have no data of mortality rates associated with severe sepsis and septic shock. Whereas other studies reported, the crude mortality rate of up to 44% attributable to carbapenem-resistant *K. pneumoniae* bacteremia is the highest so far for any microorganism causing bacteremia[3]. However, other studies determined the high ratio of CRKP isolated from urine[4, 6, 7], sputum [2, 5], pus [8], respectively. In addition, the present study investigated 61% of CRKP strains were reported from different pus sites. In contrast our neighbor country reported wound samples (49.4%) were the source of the CRKP infection that were significantly associated with the general surgery ward. This study is retrospective and has some limitations, difficult to explain, such as the length of stay and time of collection of diverse samples, which could not be ascertained.

However, Urinary tract infections (UTIs) are the most common infections in India. For the first time in our region, where the emergence of carbapenem-resistant *K. pneumoniae* strains was noted that accounted for 42% of all the urinary *K. pneumoniae* isolates. In addition, particularly noteworthy findings that isolation of CRKP from the urine was most commonly associated UTIs in higher age group, which is inconsistent with other findings[4, 6-7]. Taken together, these findings provides new insights into the clinical demonstration of CRKP bacteriuria and are useful for drawing up management strategies against XDR pathogens. Our huge sample made it possible for us to draw definitive conclusions for CRKP in UTIs; Fosfomycin 71% sensitive may be a viable option for treating CRKP in Delhi if the organism tests as susceptible and we found a growing prevalence of CRKP in the UTIs through retrospective analysis, consistent with findings from previous large surveillance studies [7].

Our data showed that constantly use or misuse of carbapenems evolving Carbapenem resistance *K. pneumoniae* is the main contributing factor for XDR and usually, the definitive step before pan drug resistance (PDR) which were worrying and is dramatically limiting treatment options [13, 14]. Therefore, older agents, such as polymyxins and fosfomycin, which were rarely implemented in the past because of efficacy and toxicity concerns, together with the newer tigecycline, have become last-resort choices.

The CRKP isolates are usually XDR and are susceptible only to Tigecycline and one or more aminoglycosides. Recently, our study showed that Tigecycline, Amikacin, and TM/SXT appear to be suitable therapies for slightly higher than 50% of the bloodstream and other infections caused by carbapenem-resistant *Klebsiella pneumoniae*, which draws attention to Tigecycline resistance, and this finding is similar to other studies [10, 13-14]. This is in contrast to other studies where Tigecycline had good activity against CRKP (95.5%)[2,8,12]. In this study, it appeared that only Tigecycline could be a good choice (susceptibility of 57%); at the same time, TM/SXT and amikacin might be an alternative, its susceptibility was only slightly higher than 40% and 50%, respectively. These findings indicate that the resistance rate of CRKP varies among different countries and period to period, even in the same country that may be explained in part by different levels of antibiotic use.

Therefore, we concluded that combination therapy including high-dose meropenem, fosfomycin, tigecycline and aminoglycosides are widely used, with suboptimal results is often required in the management of CRKP infections. Although there has been a need for rapid development of new antibiotics, such as ceftazidime-avibactam, and more effective counteractive measures, such as antimicrobial scientific stewardship and improved hospital infection control procedures,

have taken. These data highlight the need for regular surveillance of microbial resistance in India to improve infection control and guide for the use of antimicrobial agents. Newer BL/BLI (Beta-lactam and Beta-lactam inhibitors) are beyond the scope of this study.

V. CONCLUSION

Our findings concluded that the CRKP existed in north India among diverse isolates that can also be associated with the presence in a high-risk because we are sitting on a time bomb of XDR and PDR bacterial infections; if we do not take necessary steps like antibiotic stewardship in time, then we have limited or no options for treatment. Therefore, the importance of continuous monitoring of carbapenems that emphasizes the urgent need for improved infection control, antibiotic stewardship programs, and utilization of a surveillance and prevention system necessary to prevent the national and transnational spread of these isolates, especially in the case when the healthcare facilities are inadequate.

Ethical Approval: It is not applicable.

Conflicts of Interest: There are no conflicts of interest.

ACKNOWLEDGEMENTS

We are thankful to Dr. Reena Nakra, Principal Lab Director, Operations, National Reference Laboratory, *Dr. Lal Path Labs*, Delhi, for providing us operational support and Team Microbiology for technical assistance in this study.

REFERENCES RÉFÉRENCES REFERENCIAS

- Rees CA, Nasir M, Smolinska A, Lewis AE, Kane KR, Kossmann SE, Sezer O, Zucchi PC, Doi Y, Hirsch EB & Hill JE. Detection of high-risk carbapenem-resistant *Klebsiella pneumoniae* and *Enterobacter cloacae* isolates using volatile molecular profiles. *Sci Rep.* 2018; 5:8(1):13297. doi: 10.1038/s41598-018-31543-x.
- Li Y, Shen H, Zhu C, and Yu Y. Carbapenem-Resistant *Klebsiella pneumoniae* Infections among ICU Admission Patients in Central China: Prevalence and Prediction Model. *Biomed Res Int.* 2019. doi: 10.1155/2019/9767313.
- Reyes J, Aguilar AC, and Caicedo A. Carbapenem-Resistant *Klebsiella pneumoniae*: Microbiology Key Points for Clinical Practice. *Int J Gen Med.* 2019; 12: 437–446.
- Qureshi ZA, Syed A, Clarke LG, Doi Y, and Shields R K. Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant *Klebsiella pneumoniae* Bacteriuria. *Antimicrob Agents Chemother.* 2014; 58(6): 3100–3104. doi: 10.1128/AAC.02445-13.
- Moemen D & Masallat DT. Prevalence and characterization of carbapenem-resistant *Klebsiella pneumoniae* isolated from intensive care units of Mansoura University hospitals. *Egyptian Journal of Basic and Applied Sciences.* 2017; Volume 4 (1).
- Lee YJ, Huang, Ihsan CH, Lee NA, Huang IH. Molecular Epidemiology and Characterization of Carbapenem-Resistant *Klebsiella pneumoniae* Isolated from Urine at a Teaching Hospital in Taiwan. *Microorganisms.* 2021; 9, 271. <https://doi.org/10.3390/microorganisms9020271>.
- Ding Y, Wang H, Pu S, Huang S, Niu S. Resistance Trends of *Klebsiella pneumoniae* Causing Urinary Tract Infections in Chongqing, 2011–2019. *Infect Drug Resist.* 2021; 14: 475–481. doi: 10.2147/IDR.S295870.
- Gondal A J, Saleem S, Jahan S, Choudhry N, and Yasmin N. Novel Carbapenem-Resistant *Klebsiella pneumoniae* ST147 Coharboring *bla_{NDM-1}*, *bla_{OXA-48}* and Extended-Spectrum β -Lactamases from Pakistan. *Infect Drug Resist.* 2020; 13: 2105–2115. doi: 10.2147/IDR.S251532.
- Indrajith S, Mukhopadhyay AK, Chowdhury G. Molecular insights of Carbapenem resistance *Klebsiella pneumoniae* isolates with focus on multidrug resistance from clinical samples. *Journal of Infection and Public Health.* 2021; 14 (1): 131-138.
- Veeraraghavan B, Shankar C, Karunasree S, Kumari S, Ravi R, and Ralph R. Carbapenem resistant *Klebsiella pneumoniae* isolated from bloodstream infection: Indian experience. *Pathog Glob Health.* 2017; 111(5): 240–246. doi: 10.1080/20477724.2017.1340128.
- Patel G, Huprikar S, Factor S H, Jenkins SG, Calfee D P. Outcomes of Carbapenem-Resistant *Klebsiella pneumoniae* Infection and the Impact of Antimicrobial and Adjunctive Therapies. *Infection control and hospital epidemiology.* 2008; 29 (12).
- Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG and Duin DV.* Treatment and Outcomes in Carbapenem-resistant *Klebsiella pneumoniae* Bloodstream Infections. *DiagnMicrobiol Infect Dis.* 2011; 69(4): 357–362. doi: 10.1016/j.diagmicrobio.2010.10.013.
- Duin DV, Cober ED, Richter SS, Perez F, Cline M, Kaye KS, Kalayjian RC, Salata RA, Evans SR, Fowler VG, Bonomo RA. Tigecycline therapy for carbapenem-resistant *Klebsiella pneumoniae* (CRKP) bacteriuria leads to tigecycline resistance. *ClinMicrobiol Infect.* 2014; 20(12): O1117-20. doi: 10.1111/1469-0691.12714.
- Chiu SK, Chan MC, Huang LY, Lin YT, Lin JC, Lu PL, Siu LK, Chang FY, Yeh KM. Tigecycline resistance among carbapenem-resistant *Klebsiella pneumoniae*: Clinical characteristics and expression levels of efflux pump genes. *PLoS One.* 2017; 7: 12(4): e0175140. doi: 10.1371.

15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Wayne Pa: Clinical and Laboratory Standards Institute: M100-S 31; 2021.

